HomeAI · summaries
Storia in 2 fonti
Elicio’s KRAS cancer vaccine fails in Phase 2, shares plummet
Elicio's KRAS cancer vaccine failed to cut recurrence or death vs. observation in a 144-patient Phase 2 trial, plunging shares 70%; company seeks funding for a Phase 3 restricted to R0 patients.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Elicio’s KRAS cancer vaccine fails in Phase 2, shares plummet
Elicio's KRAS cancer vaccine failed to cut recurrence or death vs. observation in a 144-patient Phase 2 trial, plunging shares 70%; company seeks funding for a Phase 3 restricted…
- ·
benzinga.com
Elicio Therapeutics Pancreatic Cancer Study Disappoints - Elicio Therapeutics (NASDAQ:ELTX)
Elicio Therapeutics reports mixed Phase 2 pancreatic cancer results, identifies key patient subgroup benefit, and outlines Phase 3 plans.